Compare Erasca Inc. Common Stock (ERAS) vs Silvercorp Metals Inc. Common Shares (SVM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Erasca Inc. Common Stock vs Silvercorp Metals Inc. Common Shares — how do they compare? Erasca Inc. Common Stock trades at $14.6 (market cap $5.17B), while Silvercorp Metals Inc. Common Shares trades at $9.53 (market cap $2.21B). The key difference: Erasca Inc. Common Stock is far larger — about 2.3× Silvercorp Metals Inc. Common Shares's market cap, and Silvercorp Metals Inc. Common Shares pays a 0.25% dividend while Erasca Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 1 Days and Silvercorp Metals Inc. Common Shares for 0 Days on average.
| ERAS | SVM | |
|---|---|---|
Market Cap | $5.17B | $2.21B |
Volume | 5,313,379 | 1,113,327 |
Sector | Health | Basic Materials |
52-Week High | $22.47 | $15.71 |
52-Week Low | $2.20 | $6.09 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.95B | $1.94B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ERAS trades at $14.78, down 4.4% today, with a bullish technical signal from moving averages and a consensus analyst price target of $22.50. The company is a clinical-stage oncology firm with no revenue, reporting a net loss of $124.55 million in 2025, but holds significant liquidity and has three potential registration-enabling trials ahead. Recent news highlights FDA Fast Track designation for its lead candidate ERAS-0015.
The outlook is speculative, driven by clinical trial progress; upside exists if trials succeed, but high cash burn and shareholder investigations pose substantial risks. Investment hinges on binary outcomes from drug development, making it suitable only for risk-tolerant investors focused on biotech.
Silvercorp Metals (SVM) trades at $10.03, down 2.62% on the day, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue grew significantly from $299M in 2025 to $495M in 2026, though net income margin compressed. Analyst consensus is 60% buy with no sell ratings. Recent news highlights expansion into Ecuador and Kyrgyzstan to diversify geographic risk and a renewed share repurchase program.
The outlook is cautiously optimistic, driven by production expansion and strong operational cash flow, but tempered by execution risks in new jurisdictions and margin pressure. Key opportunities include global growth initiatives and efficient cost structure, while risks involve geopolitical exposure and volatile metal prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Erasca Inc. Common Stock
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →About Silvercorp Metals Inc. Common Shares
Silvercorp Metals Inc. is a Canadian mining company that operates underground silver-lead-zinc mines and processing plants in China, with additional exploration projects in Ecuador.
Read more on SVM →
